Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

This study is testing a new type of CAR-T cell therapy — called Meta10-19 — in people with relapsed or refractory B-cell lymphoma (a type of blood cancer that has come back or stopped responding to treatment). CAR-T therapy involves modifying a patient's own immune cells to attack cancer cells. **You may be eligible if...** - You are 18–70 years old with relapsed or refractory indolent B-cell lymphoma or diffuse large B-cell lymphoma (DLBCL) - Your cancer expresses the CD19 protein (confirmed by lab test) - You have received at least one standard treatment regimen and one salvage regimen, or your cancer came back after a stem cell transplant - You are in reasonable health **You may NOT be eligible if...** - You have had a prior CAR-T therapy less than 1 month ago - You have severe organ dysfunction - You are pregnant or breastfeeding - You have active central nervous system involvement of lymphoma - You have uncontrolled infections or autoimmune disease requiring steroids Talk to your doctor to see if this trial is right for you.